ClinicalTrials.gg
Drug

Lazertinib clinical trials

Also written JNJ-73841937 and YH25448.

studies test it
31
open now
7
in phase 3
3
first study started
2017

How each study uses lazertinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the lazertinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
19 Aug 2024 · LAZCLUZE · NDA 219008 (FDA, Drugs@FDA)
European Union
20 Jan 2025 · Lazcluze · EMEA/H/C/006074 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Lazertinib
20
Leclaza
2

Development codes

JNJ-73841937
10
YH25448
7

In one entry with another drug

Given together, or one or the other

Lazertinib+Pemetrexed+Carboplatin
2

Studies by the year they started

31 studies that test it; most in 2023 (9)

Studies that test lazertinib, by start year
YearStudies
20171
20181
20192
20204
20216
20225
20239
20242
20261

By phase

A phase 1/2 study counts in both.

Phase 1
11
Phase 2
19
Phase 3
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 17 · Other 14

Janssen Research & Development, LLC (12) · Yonsei University (4) · Yuhan Corporation (4) · Sehhoon Park (2) · Jin Hyoung Kang (2) · ETOP IBCSG Partners Foundation (1) · Latin American Cooperative Oncology Group (1) · Memorial Sloan Kettering Cancer Center (1)

Often tested with

Tested in the same studies.

Amivantamab (3)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2

Studies that test lazertinib.

Studies

Open first, then newest update. How each study uses lazertinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 31

See all 31 studies that test lazertinib →

Given beside what is tested · 6 — lazertinib is usual care or a partner of the new treatment

Codes

What other systems call lazertinib · ClinicalTrials.gg INT001347

  • MeSH (NLM) C000707992lazertinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 4A2Y23XK11LAZERTINIBConfirmed FDA, NLM, Wikidata
  • Wikidata Q105337288lazertinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C148147LazertinibOne source FDA
  • DrugBank DB16216One source Wikidata

Also registered as lazertinib mesylate (UNII WUT449BEG5).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.